Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 843


Reactive Vasodilation Predicts Mortality in Primary Systemic Light Chain (AL) Amyloidosis.

Stamatelopoulos K, Georgiopoulos GA, Athanasouli F, Nikolaou PE, Lykka M, Roussou M, Gavriatopoulou M, Laina A, Trakada G, Charakida M, Delialis D, Petropoulos I, Pamboukas C, Manios E, Karakitsou M, Papamichael C, Gatsiou A, Lambrinoudaki IV, Terpos E, Stellos K, Andreadou I, Dimopoulos MA, Kastritis E.

Circ Res. 2019 Aug 12. doi: 10.1161/CIRCRESAHA.119.314862. [Epub ahead of print]


Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH.

Int J Hematol. 2019 Aug 6. doi: 10.1007/s12185-019-02704-z. [Epub ahead of print]


Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?

Kyriazoglou A, Zagouri F, Dimopoulos MA.

ESMO Open. 2019 Jun 25;4(3):e000479. doi: 10.1136/esmoopen-2018-000479. eCollection 2019.


A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA.

Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/haematol.2019.219295. [Epub ahead of print]


Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?

Kleber M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E.

Expert Rev Hematol. 2019 Aug;12(8):651-663. doi: 10.1080/17474086.2019.1640115. Epub 2019 Jul 16.


Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Jun 25. doi: 10.1007/s00277-019-03739-2. [Epub ahead of print]


Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217448. doi: 10.3324/haematol.2019.217448. [Epub ahead of print]


Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study.

Kalapanida D, Zagouri F, Gazouli M, Tsiakou A, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA.

Onco Targets Ther. 2019 May 28;12:4195-4202. doi: 10.2147/OTT.S189329. eCollection 2019.


A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA.

Leukemia. 2019 May 22. doi: 10.1038/s41375-019-0431-y. [Epub ahead of print]


Systemic therapy in cervical cancer: 30 years in review.

Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A.

Crit Rev Oncol Hematol. 2019 May;137:9-17. doi: 10.1016/j.critrevonc.2019.02.009. Epub 2019 Feb 28. Review.


Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM.

J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.


Updates on thrombotic events associated with multiple myeloma.

Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, Migkou M, Dimopoulos MA, Terpos E.

Expert Rev Hematol. 2019 May;12(5):355-365. doi: 10.1080/17474086.2019.1604214. Epub 2019 Apr 14.


Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.

Dimopoulos MA, Laubach JP, Echeveste Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, Kumar S, Labotka R, Lu V, Berg D, Byrne C, Teng Z, Liu G, van de Velde H, Richardson PG.

Eur J Haematol. 2019 Jun;102(6):494-503. doi: 10.1111/ejh.13231. Epub 2019 May 8.


Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies.

Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Gavriatopoulou M, Sergentanis IN, Dimopoulos MA, Psaltopoulou T.

Leuk Lymphoma. 2019 Aug;60(8):1978-1990. doi: 10.1080/10428194.2018.1563693. Epub 2019 Mar 26.


Discrepancies of current recommendations in breast cancer follow-up: a systematic review.

Kyriazoglou A, Zagouri F, Fotiou D, Dimitrakakis C, Marinopoulos S, Zakopoulou R, Kaparelou M, Zygogianni A, Dimopoulos MA.

Breast Cancer. 2019 Sep;26(5):681-686. doi: 10.1007/s12282-019-00963-6. Epub 2019 Mar 18.


Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.

Trakada G, Kastritis E, Gavriatopoulou M, Velentza L, Fotiou D, Ziogas DC, Panagiotidis I, Eleutherakis-Papaiakovou E, Roussou M, Migkou M, Kanellias N, Ntanasis-Stathopoulos I, Kallianos A, Terpos E, Dimopoulos MA.

Ann Hematol. 2019 Jun;98(6):1427-1434. doi: 10.1007/s00277-019-03641-x. Epub 2019 Mar 5.


A 50-Year-Long Study of Waldenström Macroglobulinemia.

Kastritis E, Dimopoulos MA.

Mayo Clin Proc. 2019 Mar;94(3):394-396. doi: 10.1016/j.mayocp.2019.01.021. No abstract available.


Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop.

Bagratuni T, Sklirou AD, Kastritis E, Liacos CI, Spilioti C, Eleutherakis-Papaiakovou E, Kanellias N, Gavriatopoulou M, Terpos E, Trougakos IP, Dimopoulos MA.

Sci Rep. 2019 Mar 1;9(1):3245. doi: 10.1038/s41598-019-39672-7.


Anti-BCMA antibodies in the future management of multiple myeloma.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E.

Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326. doi: 10.1080/14737140.2019.1586539. Epub 2019 Mar 18.


The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG).

Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG, Terpos E.

Blood Cancer J. 2019 Feb 26;9(3):27. doi: 10.1038/s41408-019-0187-7.


Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K.

Blood Cancer J. 2019 Feb 22;9(3):23. doi: 10.1038/s41408-019-0181-0.


Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. No abstract available.


Myeloma bone disease: from biology findings to treatment approaches.

Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA.

Blood. 2019 Apr 4;133(14):1534-1539. doi: 10.1182/blood-2018-11-852459. Epub 2019 Feb 13. Review.


Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.

Gonzalez-McQuire S, Dimopoulos MA, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S.

MDM Policy Pract. 2019 Jan 17;4(1):2381468318814253. doi: 10.1177/2381468318814253. eCollection 2019 Jan-Jun.


Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.


The extended 4-year follow-up results of the ELOQUENT-2 trial.

Gavriatopoulou M, Terpos E, Dimopoulos MA.

Oncotarget. 2019 Jan 4;10(2):82-83. doi: 10.18632/oncotarget.26527. eCollection 2019 Jan 4. No abstract available.


Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Hulin C, de la Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa AM, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D Jr, Potamianou A, van de Velde H, Delforge M.

Health Sci Rep. 2018 Dec 7;2(1):e104. doi: 10.1002/hsr2.104. eCollection 2019 Jan.


Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.

Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA.

Cancer J. 2019 Jan/Feb;25(1):2-10. doi: 10.1097/PPO.0000000000000348.


High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

Thakurta A, Ortiz M, Blecua P, Towfic F, Corre J, Serbina NV, Flynt E, Yu Z, Yang Z, Palumbo A, Dimopoulos MA, Gutierrez NC, Goldschmidt H, Sonneveld P, Avet-Loiseau H.

Blood. 2019 Mar 14;133(11):1217-1221. doi: 10.1182/blood-2018-10-880831. Epub 2019 Jan 28.


Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant.

Liapis K, Panagopoulou P, Charitaki E, Rowczenio D, Gilbertson J, Papathoma A, Kostopoulou M, Dimopoulos MA, Gillmore JD, Kastritis E.

Amyloid. 2019 Mar;26(1):52-53. doi: 10.1080/13506129.2018.1562442. Epub 2019 Jan 26. No abstract available.


A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options.

Moutafi M, Ziogas DC, Michopoulos S, Bagratuni T, Vasileiou V, Verga L, Merlini G, Palladini G, Matsouka C, Dimopoulos MA, Kastritis E.

BMC Med Genet. 2019 Jan 21;20(1):23. doi: 10.1186/s12881-019-0755-5.


Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.

Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA.

Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20.


Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study.

Kalapanida D, Zagouri F, Gazouli M, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA.

Oncotarget. 2018 Dec 11;9(97):36906-36913. doi: 10.18632/oncotarget.26385. eCollection 2018 Dec 11.


Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.

Terpos E, Katodritou E, Symeonidis A, Zagouri F, Gerofotis A, Christopoulou G, Gavriatopoulou M, Christoulas D, Ntanasis-Stathopoulos I, Kourakli A, Konstantinidou P, Kastritis E, Dimopoulos MA.

Int J Cancer. 2019 Jul 15;145(2):559-568. doi: 10.1002/ijc.32125. Epub 2019 Jan 22.


Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.

Gavriatopoulou M, Fotiou D, Koloventzou U, Roussou M, Migkou M, Ntanasis-Stathopoulos I, Kanellias N, Ziogas DC, Panagiotidis I, Gika D, Eleutherakis-Papaiakovou E, Terpos E, Kastritis E, Dimopoulos MA.

Leuk Lymphoma. 2019 Mar;60(3):619-628. doi: 10.1080/10428194.2018.1509323. Epub 2019 Jan 10.


How I treat rituximab refractory patients with WM.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.

Oncotarget. 2018 Dec 7;9(96):36824-36825. doi: 10.18632/oncotarget.26411. eCollection 2018 Dec 7. No abstract available.


Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies.

Psaltopoulou T, Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Riza E, Dimopoulos MA.

Int J Cancer. 2019 Jul 15;145(2):347-359. doi: 10.1002/ijc.32109. Epub 2019 Feb 12.


Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature.

Kyriazoglou A, Liontos M, Papadopoulos C, Bilali A, Kostouros E, Pagoni S, Doumas K, Dimopoulos MA, Bamias A.

Clin Genitourin Cancer. 2019 Apr;17(2):e360-e364. doi: 10.1016/j.clgc.2018.11.022. Epub 2018 Dec 4. No abstract available.


Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.

Terpos E, Kastritis E, Ntanasis-Stathopoulos I, Christoulas D, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Fotiou D, Ziogas DC, Migkou M, Roussou M, Trougakos IP, Gavriatopoulou M, Dimopoulos MA.

Am J Hematol. 2019 Apr;94(4):400-407. doi: 10.1002/ajh.25392. Epub 2019 Jan 10.


How I treat elderly patients with plasma cell dyscrasias.

Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA.

Aging (Albany NY). 2018 Dec 18;10(12):4248-4268. doi: 10.18632/aging.101707.


Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.


Management of uterine sarcomas and prognostic indicators: real world data from a single-institution.

Kyriazoglou A, Liontos M, Ziogas DC, Zagouri F, Koutsoukos K, Tsironis G, Tsiara A, Kaparelou M, Zakopoulou R, Thomakos N, Haidopoulos D, Papaspyrou I, Rodolakis A, Bamias A, Dimopoulos MA.

BMC Cancer. 2018 Dec 13;18(1):1247. doi: 10.1186/s12885-018-5156-1.


Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. No abstract available.


Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.

Efentakis P, Kremastiotis G, Varela A, Nikolaou PE, Papanagnou ED, Davos CH, Tsoumani M, Agrogiannis G, Konstantinidou A, Kastritis E, Kanaki Z, Iliodromitis EK, Klinakis A, Dimopoulos MA, Trougakos IP, Andreadou I, Terpos E.

Blood. 2019 Feb 14;133(7):710-723. doi: 10.1182/blood-2018-06-858415. Epub 2018 Nov 27.


All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Dimopoulos MA, Grosicki S, Jędrzejczak WW, Nahi H, Gruber A, Hansson M, Gupta N, Byrne C, Labotka R, Teng Z, Yang H, Grzasko N, Kumar S.

Eur J Cancer. 2019 Jan;106:89-98. doi: 10.1016/j.ejca.2018.09.011. Epub 2018 Nov 22.


IMiDs for myeloma induced renal impairment.

Gavriatopoulou M, Terpos E, Dimopoulos MA.

Oncotarget. 2018 Oct 26;9(84):35476-35477. doi: 10.18632/oncotarget.26270. eCollection 2018 Oct 26. No abstract available.


Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA.

Br J Haematol. 2019 Feb;184(4):536-546. doi: 10.1111/bjh.15679. Epub 2018 Nov 20.


Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Salman Z, Buske C.

N Engl J Med. 2018 Nov 15;379(20):1975-1976. doi: 10.1056/NEJMc1809505. No abstract available.


Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).

Tsironis G, Koutsoukos K, Athanasakis K, Tsiara A, Tzannis K, Gerolympou M, Visvikis A, Oikonomopoulos G, Kollia A, Giannopoulou E, Dimitra M, Kostouros E, Papatsoris A, Dellis A, Stravodimos K, Varkarakis I, Samantas E, Aravantinos G, Kentepozidis N, Christodoulou C, Bozionelou V, Dimopoulos MA, Bamias A.

Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):491-501. doi: 10.1080/14737167.2019.1546121. Epub 2018 Nov 19.


Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

Supplemental Content

Loading ...
Support Center